[go: up one dir, main page]

AR031226A1 - 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen - Google Patents

1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen

Info

Publication number
AR031226A1
AR031226A1 ARP000105117A ARP000105117A AR031226A1 AR 031226 A1 AR031226 A1 AR 031226A1 AR P000105117 A ARP000105117 A AR P000105117A AR P000105117 A ARP000105117 A AR P000105117A AR 031226 A1 AR031226 A1 AR 031226A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
phenyl
methyl
conh2
Prior art date
Application number
ARP000105117A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR031226A1 publication Critical patent/AR031226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

1,1'-bifenil-2-carboxamidas 2'-sustituidas, que comprenden un compuesto de la formula (1) en la cual: R(1) es C(O)OR(9), SO2R(10), COR(11), C(O)NR(12)R(13) o C(S)NR(12)R(13); R(9) es CxH2x-R(14); x es 0, 1, 2, 3 o 4, no pudiendo x ser 0 si R(14) es OR(15) o SO2Me; R(14) es alquilo C1-6, cicloalquilo C3-11, CF3, OCF3, C2F5, C3F7, CH2F, CHF2, OR(15), SO2Me, fenilo, naftilo, bifenililo, furilo, tienilo o un heteroaromático N-portador C1-9; donde fenilo, naftilo, bifenililo, furilo, tienilo y el heteroaromático N-portador están sustituidos o no por 1, 2, o 3 sustituyentes seleccionados del grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metil sulfonilamino; R(15) es alquilo C1-5, cicloalquilo C3-6, CF3 o fenilo que es no sustituido o sustituido por 1, 2 o 3 sustituyentes seleccionados del grupo consistente en F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metilsulfonilo y metil sulfonilamino; R(10), R(11) y R(12) independientemente el uno del otro son definidos como para R(9); R(13) es hidrogeno, alquilo C1-4 o CF3; R(2) es hidrogeno, alquilo C1-4 o CF3; R(3) es CyH2y-R(16); y es 0, 1, 2, 3 o 4, no pudiendo y ser 0 si R(16) es OR(17) o SO2Me; R(16) es alquilo C1-6, cicloalquilo C3-11, CF3, C2F5, C3F7, CH2F, CHF2, OR(17), SO2Me, fenilo, naftilo, furilo, tienilo o un heteroaromático C1-9 que contiene N, en lo cual fenilo, naftilo, furilo, tienilo y el heteroaromático que lleva N están sin sustituir o están sustituidos por 1, 2 o 3 sustituyentes seleccionados de entre el grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metil sulfonilamino; R(17) es hidrogeno, alquilo C1-5, cicloalquilo C3-5, CF3, fenilo o 2-, 3- o 4-piridilo, donde el fenilo o el 2-, 3- o 4-piridilo son no sustituidos o son sustituidos por 1, 2 o 3 sustituyentes seleccionados del grupo consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metil sulfonilamino; o R(3) es CHR(18)R(19); R(18) es hidrogeno o CzH2z-R(16), donde R(16) se define como se indica anteriormente; z es 0, 1, 2 o 3; R(19) es COOH, CONH2, CONR(20)R(21), COOR(22) o CH2OH; R(20) es hidrogeno, alquilo C1-5, CvH2v-CF3 o CwH2w-fenilo, donde el anillo fenilo es no sustituido o es sustituido por 1, 2 o 3 sustituyentes seleccionados de grupos consistente en F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo y metil sulfonilamino; v es 0, 1, 2 o 3; w es 0, 1, 2 o 3; R(21) es hidrogeno o alquilo C1-5; R(22) es alquilo C1-5; R(4) es hidrogeno, alquilo C1-6 o CF3; o R(3) y R(4) juntos son una cadena de 4 o 5 grupos metileno, de los cuales un grupo metileno puede ser reemplazado por -O-, -S-, -NH-, -N(metil)- o -N(bencil)-; R(5), R(6), R(7) y R(8), independientemente el uno del otro son hidrogeno, F, Cl, Br, I, CF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, alquilo C1-4, alcoxi C1-4, dimetilamino, sulfamoílo, metil sulfonilo o metil sulfonilamino; R(30) y R(31), independientemente el uno del otro son hidrogeno o alquilo C1-3; o R(30) y R(31), juntos forman una cadena de 2 grupos metileno; y sus sales farmacéuticamente aceptables; procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmacéuticas que las contienen, activos como anti-arrítmicos, en especial para el tratamiento y profilaxis de las arritmias auriculares, por ejemplo la fibrilacion auricular (atrial Fibrillation, AF) o el aleteo o fluter auricular (atrial fluter).
ARP000105117A 1999-10-02 2000-09-28 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen AR031226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19947457A DE19947457A1 (de) 1999-10-02 1999-10-02 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
AR031226A1 true AR031226A1 (es) 2003-09-17

Family

ID=7924254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105117A AR031226A1 (es) 1999-10-02 2000-09-28 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen

Country Status (32)

Country Link
EP (1) EP1222163B1 (es)
JP (1) JP4713800B2 (es)
KR (1) KR100722178B1 (es)
CN (1) CN1195738C (es)
AR (1) AR031226A1 (es)
AT (1) ATE332890T1 (es)
AU (1) AU766365B2 (es)
BR (1) BR0014465B1 (es)
CA (1) CA2385859C (es)
CY (1) CY1106178T1 (es)
CZ (1) CZ302591B6 (es)
DE (2) DE19947457A1 (es)
DK (1) DK1222163T3 (es)
EE (1) EE05000B1 (es)
ES (1) ES2265985T3 (es)
HK (1) HK1048986B (es)
HR (1) HRP20020264B1 (es)
HU (1) HU229046B1 (es)
IL (2) IL148870A0 (es)
ME (1) MEP60908A (es)
MX (1) MXPA02002691A (es)
NO (1) NO327709B1 (es)
NZ (1) NZ518065A (es)
PL (1) PL204034B1 (es)
PT (1) PT1222163E (es)
RS (1) RS50387B (es)
RU (1) RU2252214C2 (es)
SK (1) SK286756B6 (es)
TR (1) TR200200883T2 (es)
TW (1) TWI270541B (es)
WO (1) WO2001025189A1 (es)
ZA (1) ZA200202521B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266346A1 (en) 2000-06-28 2002-01-08 Takeda Chemical Industries Ltd. Biphenyl compound
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JPWO2002098840A1 (ja) 2001-06-04 2004-09-16 エーザイ株式会社 カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7507753B2 (en) 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
JP4690889B2 (ja) * 2002-10-24 2011-06-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング メチレン尿素誘導体
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
BRPI0710946A2 (pt) * 2006-04-27 2012-03-06 Sanofi-Aventis Deutschland Gmbh inibidores dos canais de Íon task-1 e task-3
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
SG175703A1 (en) * 2009-06-03 2011-12-29 Sanofi Aventis Deutschland Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (es) 2011-07-01 2018-04-28
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU766365B2 (en) 2003-10-16
TWI270541B (es) 2007-01-11
PL354322A1 (en) 2004-01-12
TR200200883T2 (tr) 2002-09-23
SK286756B6 (sk) 2009-05-07
HRP20020264B1 (en) 2010-08-31
CN1195738C (zh) 2005-04-06
ATE332890T1 (de) 2006-08-15
AU7777800A (en) 2001-05-10
CY1106178T1 (el) 2011-06-08
RU2252214C2 (ru) 2005-05-20
HUP0203505A3 (en) 2004-01-28
KR20020038791A (ko) 2002-05-23
RU2002111561A (ru) 2004-01-20
PL204034B1 (pl) 2009-12-31
NZ518065A (en) 2004-08-27
DE19947457A1 (de) 2001-04-05
KR100722178B1 (ko) 2007-05-29
EE05000B1 (et) 2008-04-15
CZ302591B6 (cs) 2011-07-27
HU229046B1 (hu) 2013-07-29
PT1222163E (pt) 2006-10-31
ES2265985T3 (es) 2007-03-01
MEP60908A (en) 2011-05-10
DE50013167D1 (de) 2006-08-24
SK4382002A3 (en) 2002-08-06
NO20021398D0 (no) 2002-03-20
ZA200202521B (en) 2002-12-24
EP1222163A1 (de) 2002-07-17
RS50387B (sr) 2009-12-31
BR0014465B1 (pt) 2011-12-27
NO20021398L (no) 2002-05-31
MXPA02002691A (es) 2002-07-30
JP2003511363A (ja) 2003-03-25
NO327709B1 (no) 2009-09-14
HRP20020264A2 (en) 2004-02-29
EE200200160A (et) 2003-04-15
DK1222163T3 (da) 2006-11-13
WO2001025189A1 (de) 2001-04-12
CA2385859C (en) 2009-11-24
BR0014465A (pt) 2002-06-11
IL148870A (en) 2007-05-15
HK1048986A1 (en) 2003-04-25
CZ20021144A3 (cs) 2002-06-12
HK1048986B (zh) 2005-07-29
HUP0203505A2 (hu) 2003-03-28
CA2385859A1 (en) 2001-04-12
CN1373750A (zh) 2002-10-09
IL148870A0 (en) 2002-09-12
YU24402A (sh) 2005-06-10
EP1222163B1 (de) 2006-07-12
JP4713800B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
AR031226A1 (es) 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen
AR033408A1 (es) Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen
AR032781A1 (es) Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
RU2003121236A (ru) Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием
RU2003120080A (ru) Орто-замещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции
HUP0203902A2 (hu) Szubsztituált oxazolidinonok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR029210A1 (es) DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS
CA2430273A1 (en) Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
NO20050668L (no) 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido og 2,3-dihydro-2H-pyrrolo [2,1-B]-kinazolinon-derivater
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
UY28510A1 (es) Compuestos quimicos
AR008386A1 (es) DERIVADOS DE BENZIMIDAZOL CON ACTIVIDAD ANTIHISTAMINICA Y COMPOSICIoN FARMACÉUTICA ANTIHISTAMINICA QUE LOS CONTIENE.
RU2006144069A (ru) Режим приема контрацептива с антагонистом рецептора прогестерона и набор для приема
AR115303A1 (es) Moduladores de calpaína y usos terapéuticos de los mismos
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
AR044830A1 (es) Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester
ES2045189T3 (es) Nuevos agentes anti-arritmicos i.
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
AR072591A1 (es) Nitratos de isosorbida, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades vasculares.

Legal Events

Date Code Title Description
FG Grant, registration